This Phase 2 study is designed to evaluate multiple doses of an anticholinergic-containing medication and identify the dose or doses that may effectively reduce axillary sweating in hyperhidrotic subjects. The anticholinergic agent being studied is designated WL8713.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
195
Watson Clinical Site
San Diego, California, United States
Gravimetric measurement of sweat production
Change from baseline in mean (bilateral average) sweat weight at Week 6 (LOCF)
Time frame: 6 weeks
Hyperhidrosis Disease Severity Scale (HDSS) scores
Percentage of subjects with a change from baseline in HDSS scores of at least -2 points at Week 6 (LOCF)
Time frame: 6 weeks
Dermatology Life Quality Index (DLQI) scores
Change from baseline in DLQI total score at Week 6 (LOCF)
Time frame: 6 weeks
Global Assessment of Disease State responses
Global Assessment of Disease State score at Week 6 (LOCF)
Time frame: 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.